Navigation Links
Important Drug Information Notice Regarding Sodium Thiosulfate Injection, USP, 10% (100mg/mL), 10mL Single Dose Vials and 25% (250mg/mL), 50mL Single Dose Vials
Date:3/29/2011

SHIRLEY, N.Y., March 29, 2011 /PRNewswire/ -- Yesterday American Regent, Inc. issued a letter regarding a product recall from February 2011. The text of the letter follows:

Dear Healthcare Professional,

Recently, American Regent, Inc. recalled Sodium Thiosulfate Injection, USP, 10%, 10mL Single Dose Vials, Lot #0056, because some of the vials of this lot contained translucent visible particles that have been identified as glass delamination.  The particles detected in Lot #0056 ranged in size from < 5 microns to about 350 microns.

Potential adverse events after intravenous administration include damage to blood vessels in the lung, localized swelling, and granuloma formation.  American Regent recalled Sodium Thiosulfate Injection lot #0056 on February 2, 2011 in consideration of the potential for safety issues if this lot of product was administered to patients.

Retention samples of all other lots and sizes of this product in commercial distribution (see below for sizes and NDC #s) have been visually re-inspected and have not exhibited visible evidence of glass delamination or translucent visible particles indicative of glass delamination.  Our retention inspection program requires samples be visually inspected at appropriate intervals to ensure there is no evidence of deterioration in our products.  American Regent has already taken other steps, such as changing the source of glass used, to help address this problem.

As a precautionary measure, American Regent recommends that, until further notice, a filter be used for the withdrawal and administration of this product.  

The following procedure should be used for the compounding and administration of Sodium Thiosulfate Injection, USP (this does not apply to the recalled Lot #0056, which should not be administered).

  1. Perform a visual inspection on the vial prior to withdrawal of the contents. DO NOT USE IF PARTICULATES ARE PRESENT.  USE A NEW VIAL.
  2. Use a 5 micron filter needle to withdraw the required calculated volume of Sodium Thiosulfate Injection, USP.
  3. Remove the filter needle and attach a standard needle to the syringe before adding to a larger volume of IV fluid and/or prior to patient administration.
  4. Visually inspect the final IV admixture solution.  DO NOT USE IF PARTICULATES ARE VISIBLE.  USE A NEW VIAL.
  5. Use a 0.22 micron in-line filter when administering the final IV admixture to patients.

If particulates are observed, or if you require additional information, please call American Regent at 1-877-788-3232 then press 2 for the Professional Services Department (Monday - Friday:  9:00am-5:00pm ET) or by e-mail at inquiry@americanregent.com

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, or regular mail or by fax.

  • Online: www.fda.gov/medwatch/report.htm  

  • Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm . Mail to address on the pre-addressed form.

  • Fax: 1-800-FDA-0178

  • This letter is being distributed with the knowledge of the U.S. Food & Drug Administration.

    We apologize for any inconvenience that you may experience and appreciate your cooperation in this matter.

    Sincerely yours,

    Walter A. Tozzi, R.Ph., MS, MBA
    Sr. Director, Marketing & Professional ServicesSodiumThiosulfate Injection, USP

    Vial Sizes

    NDC #10% (100mg/mL)

    10mL SDV

    0517-1019-0525% (250mg/mL)

    50mL SDV

    0517-5019-01
    '/>"/>

    SOURCE American Regent, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Important Drug Information Notice Regarding Potassium Phosphates Injection, USP, 3 mM/mL Phosphorous; 4. 4 mEq/mL Potassium: 5 mL, 15 mL and 50 mL Single Dose Vials
    2. PNP Therapeutics Meets Important Financial and Regulatory Objectives in Development of New Cancer Therapies
    3. Urgent: OTC DRUG Nationwide Recall--Important information for patients about IV PREP Antiseptic Wipes
    4. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
    5. Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care
    6. Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration
    7. Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Groups Alcohol Prep Products
    8. AVMA Offers Important Guidance to DEA on New Controls for Induction Agent—Propofol
    9. Activity Against Key Drug-Resistant Pathogens is the Most Important Attribute Influencing Surveyed Physicians Antibiotic Selection for Nosocomial Pneumonia in the U.S.
    10. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
    11. Global Med Technologies(R) Solution of Choice for Important Regional Blood Center
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/5/2016)... 2016 Research and Markets has announced the ... 5 EU Markets"  report to their offering.  ,     (Logo: ... on the current Positron Emission Tomography (PET) scanner and cyclotron ... which includes France , Germany ... and the United Kingdom . ...
    (Date:5/5/2016)... 2016 Research and ... Thalassaemia Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Competitive Landscape Highlights - 2016, provides comprehensive ... Thalassaemia market valuations and forecast, Thalassaemia products ...
    (Date:5/4/2016)... , May 4, 2016 ... Market Research entitled "Brain Computer Interface Market - Global Industry ... 2024," the  global brain computer interface (BCI) market  is expected ... The market is estimated to expand at a CAGR ... to 2024. A BCI device provides collaboration ...
    Breaking Medicine Technology:
    (Date:5/5/2016)... ... May 05, 2016 , ... Florida Hospital Pepin Heart ... fibrillation (A-Fib) an alternative to long-term warfarin medication with the newly approved WATCHMAN ... of 2015, Florida Hospital Pepin Heart Institute doctors successfully implanted the Watchman device ...
    (Date:5/5/2016)... ... May 05, 2016 , ... ... the Wharton Seminars for Business Journalists , led by the Wharton ... business and economic issues.  This one-day program at the Wharton School’s San ...
    (Date:5/5/2016)... ... May 05, 2016 , ... ... in all U.S. states and certain Canadian provinces is now available from the ... Research Institute (WCRI). , The report, Workers’ Compensation Laws as of ...
    (Date:5/5/2016)... ... May 05, 2016 , ... Tim Dieter has ... families of greater Dubuque, IA. The current campaign fundraises for Veteran’s Freedom Center ... Donations to Veteran’s Freedom Center may now be made here: http://www.veteransfreedomcenter.com/donate/ . ...
    (Date:5/5/2016)... ... 05, 2016 , ... Dr. Benjamin Stong of Kalos Facial Plastic Surgery, LLC ... Stong is double board certified and the only facial plastic surgeon in Atlanta to ... Non-surgical therapies such as stem cells can be used to provide stabilization to hair ...
    Breaking Medicine News(10 mins):